STADA Arzneimittel AG — AGM Information 2006

Jun 14, 2006

News Details

Corporate | 14 June 2006 15:06

STADA AGM: Executive Board confirms further growth course in sales and earnings

Corporate-news transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— At STADA Arzneimittel AG’s Annual General Meeting which took place today, on June 14, 2006 in the Congress Center of the Messe Frankfurt, the Executive Board, in their remarks, confirmed the expectation of the further growth course in sales and earnings. For 2006, the Executive Board continues to expect, from today’s perspective, robust operative growth within the Group with a stronger increase in earnings than in sales. At first, STADA’s Chief Executive Officer, Hartmut Retzlaff, in his AGM speech, reported on the past fiscal year 2005 – for STADA the tenth record year in a row both in terms of sales and earnings. In his remarks, Retzlaff then went into the strategy of the company, which is primarily characterized by strategic consistency and, concurrently, operative flexibility – in the view of the Executive Board the basis for STADA’s sustained success. In this connection, the STADA CEO emphasized once again that ‘without a doubt, independence is essential to this strategic consistency for the company’ – It is neither strategically nor operatively necessary for STADA to be taken over. The Executive Board continues to be optimistic about the current fiscal year. Despite comprehensive price reductions in the German market as of July 1, 2006, STADA sees no need to change the Group’s growth prognosis because these price reductions have been, for quite some time, a part of corporate planning and the remaining part can be offset by budget reserves due to the positive international business. The Annual General Meeting agreed with the proposal from the Executive Board and Supervisory Board on a dividend that is unchanged from the previous year in the amount of EUR 0.39 per common share. The total dividend payments of EUR 20.8 million thus represents 40% of net income. Additionally, the Executive Board and the Supervisory Board were confirmed with nearly 100% approval. The exact voting results for these and all other points on the agenda (among other things, various changes to the articles of incorporation) can be found at STADA’s website under www.stada.com. Further information: STADA Arzneimittel AG / Corporate Communications / Stadastrasse 2–18 / 61118 Bad Vilbel / Germany / Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communications@stada.de Or visit our website at www.stada.com. (c)DGAP 14.06.2006 ————————————————————————— Language: English Issuer: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Deutschland Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 email: communications@stada.de WWW: www.stada.de ISIN: DE0007251803, DE0007251845, DE000AOHN446 WKN: 725180, 725184, AOHN44 indices: MDAX Listed: Amtlicher Markt in Frankfurt (Prime Standard), Düsseldorf End of News DGAP News-Service —————————————————————————